ClinicalTrials.gg
TerminatedNCT04968184Clarion-CKDUpdated Nov 4, 2026Results posted

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

A Phase 3 interventional study of Placebo and KBP-5074 in Chronic Kidney Diseases, sponsored by Novo Nordisk A/S. Terminated at 215 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Interim futility analysis showed primary endpoint not achieved
Updated Nov 4, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
666
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S — 5 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Novo Nordisk A/S.

Enrollment
3rd of 18
666 · median 128
Started
2021
with 3 others
Phase 3
5 of 29
1 open now
Registered
12th of 29
by date

Among the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 12th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

5 of the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage 3b/4 chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula [eGFR {EPI}] ≥15 to ≤44 mL/min/1.73 m\^2) and uncontrolled hypertension (systolic blood pressure (SBP) ≥140 and \<180 mm Hg and taking 2 or more antihypertensive medications.

Read the detailed description

Participants in this study will be recruited, screened, and enrolled at approximately 140 study sites globally.

The study will consist of the following periods:

  1. Pretreatment Phase: This will include prescreening assessment and screening period of up to 4 weeks and 2-week Open-label placebo Run-In period.
  2. A 24-week Double-blind Treatment Period (Randomization to Week 24) will include: An initial 12-week (Randomization to Week 12) and second 12-week (Week 12 to Week 24) treatment period and a second 12-week treatment period (Week 12 to Week 24), during both the periods study drug will be titrated.
  3. A 24-week Open-label Treatment Period (Week 24 to Week 48) during which eligible participants will receive Open-label KBP-5074.
  4. A 4-week Randomized Double-blind Withdrawal Period (Week 48 to Week 52) during which eligible participants will be randomized to continue their current KBP-5074 dose at the end of Open-label treatment or receive matching placebo for 4 weeks.
  5. A 4-week post-treatment Follow-Up Period (Week 52 to Week 56).

During, 24-week Double-blind Treatment Period, 24-week Open-label Treatment Period, and at 4-week Randomized Double-blind Withdrawal Period, the background antihypertensive medications change may or may not be allowed.

At Double-blind Treatment Period, eligible participants will be randomly assigned in a 1:1 ratio to KBP-5074 0.25 mg or matching placebo once daily (QD).

At the Randomized Double-blind Withdrawal Period, participants who meet the randomized withdrawal criteria will be randomly assigned in a 1:1 ratio to continue their current KBP-5074 dose at the end of the Open-label Treatment Period or matching placebo QD.

The study design included a pre-planned futility determination by an Independent Data Monitoring Committee (IDMC).

The trial was originally sponsored by KBP Biosciences PTE Ltd, but sponsorship was transferred to Novo Nordisk after the trial was terminated following the futility determination by IDMC.

03

Conditions studied

  • Chronic Kidney Diseases

Keywords

  • Stage 3b/4 chronic kidney disease
  • Hypertension
  • Uncontrolled Hypertension
  • Blood pressure
  • Mineralocorticoid Receptor Antagonist
  • Randomized withdrawal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) must be ≥19 to \<45 kg/m\^2 at the Screening Visit
  • Participant must have uncontrolled hypertension defined as meeting both of the following criteria:

    • The participant has a resting seated trough cuff SBP ≥140 mm Hg at the Screening Visit (Visit 1), and at the start (Visit 2) and end (Visit 3) of the Run-In Period
    • The participant is taking 2 or more antihypertensive medications that have been titrated upward as tolerated to hypertension target doses per local SoC and have been stable (i.e., without any dose adjustments) from 4 weeks before the Screening Visit (Visit 1) through the end of the Run-In Period (Visit 3)
  • The participant must have Stage 3b ( [EPI] ≥30 and ≤44 mL/min/1.73 m\^2) or Stage 4 (eGFR [EPI] ≥15 and \<30 mL/min/1.73 m\^2) CKD.

Exclusion criteria

Exclusion Criteria:

  • Participant has a resting seated trough cuff SBP ≥180 mm Hg at the Screening Visit (Visit 1) or at the start (Visit 2) or end (Visit 3) of the Run-In Period
  • Participant has a serum potassium level >4.8 mmol/L during the Screening or Run-In Periods
  • Participant has had a serum potassium level >5.6 mmol/L within 2 weeks before the Screening Visit (Visit 1)
  • Participant has been hospitalized for hyperkalemia within the 3 months before the Randomization Visit (Visit 3)
  • Participant was not compliant with taking placebo during the Run-in Period or participant was not compliant with background antihypertensive medications during the Run-in Period as assessed at the Randomization Visit (Visit 3)
  • Participant has taken an mineralocorticoid receptor antagonist (MRA), a potassium-sparing diuretic, or chronic potassium supplements during the 4 weeks before the Screening Visit (Visit 1)
  • Participant has taken potassium binders for the treatment of hyperkalemia during the 3 months before the Screening Visit (Visit 1)
  • Participant has taken a strong cytochrome P450 (CYP) inducer or strong CYP3A4 inhibitor during the 7 days before the Randomization Visit (Visit 3)
  • Participant has taken a prohibited traditional Chinese medication during the 28 days prior to Screening Visit (Visit 1).
  • Participant was administered any other product within 4 weeks or 5 half-lives (whichever is longer) prior to the Screening Visit (Visit 1).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
666 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Open-label Placebo Run-In Period: All eligible participants will receive matching placebo, for approximately 2 weeks, during the Open-label placebo Run-In period. Double-blind Treatment Period: All eligible participants will receive matching placebo, from week 2 thru week 24 during the Double-blind treatment Period Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52. Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56.

    Drug: Placebo

  • Experimental
    KBP-5074

    Open-label Placebo Run-In period: All eligible participants will receive matching placebo, for approximately 2 weeks during the Open-label placebo Run-In period. Double-blind Treatment Period: All eligible participants will receive KBP-5074, from week 2 thru week 24 during the Double-blind Treatment Period Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52. Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56.

    Drug: KBP-5074

Interventions

  • DrugPlacebo

    Participants will orally receive placebo matching to KBP-5074 tablets QD.

  • Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD.

06

What researchers measure

Primary outcomes

  1. Change in Seated Trough Cuff Systolic Blood Pressure (SBP) From Baseline to Week 12

    Efficacy of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for KBP-5074 dose regimen compared to placebo, was evaluated.

    Time frame: From baseline to Week 12

  2. Change in Seated Trough Cuff SBP From Week 48 to Week 52

    Durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for the KBP-5074 dose regimen compared to placebo, was evaluated.

    Time frame: From Week 48 to Week 52

Secondary outcomes

  1. Change in Seated Trough Cuff SBP From Baseline to Week 24

    Efficacy and durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP, were evaluated.

    Time frame: From baseline to Week 24

  2. Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 12

    Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, was evaluated.

    Time frame: From baseline to Week 12

  3. Changes in Urinary Albumin: Creatinine Ratio (UACR) From Baseline to Week 12 for Participants With UACR ≥30 mg/g at Baseline

    Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline, was evaluated.

    Time frame: From baseline to Week 12

  4. Percentage Changes in UACR From Baseline to Week 12 and Week 24 for Participants With UACR ≥30 mg/g at Baseline

    Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g at baseline, was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.

    Time frame: From baseline to Week 12 and Week 24

  5. Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 24

    Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP was evaluated.

    Time frame: From baseline to Week 24

  6. Changes in Seated Trough Cuff DBP From Baseline to Week 48

    Effect of KBP-5074 on DBP by assessing change in seated trough cuff SBP was evaluated.

    Time frame: From baseline to Week 48

  7. Changes in Seated Trough Cuff SBP From Baseline to Week 48

    Effect of KBP-5074 on SBP by assessing change in seated trough cuff SBP was evaluated.

    Time frame: From baseline to Week 48

  8. Changes in UACR From Baseline to Week 24 for Participants With UACR ≥30 mg/g at Baseline

    Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline was evaluated.

    Time frame: From baseline to Week 24

  9. Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Macroalbuminuria

    Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated.

    Time frame: From baseline to Week 12, Week 24, and Week 48

  10. Percentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Macroalbuminuria

    Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated.

    Time frame: From baseline to Week 12, Week 24, and Week 48

  11. Change in Seated Trough Cuff DBP From Week 48 to Week 52

    Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP was evaluated.

    Time frame: From Week 48 to Week 52

  12. Change in UACR From Week 48 to Week 52 for Participants With UACR ≥30 mg/g at Baseline

    Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.

    Time frame: Week 48 to Week 52

  13. Percentage Change in UACR From Week 48 to Week 52 in Participants With UACR ≥30 mg/g at Baseline

    Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.

    Time frame: From Week 48 to Week 52

  14. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    The safety and tolerability of KBP-5074 was evaluated. A treatment emergent adverse event (TEAE) was defined as any AE with onset during or after first dose and before 4 weeks after last dose of study drug, or any preexisting AE/condition that worsened during this period. Selected TEAEs include Hyperkalemia, Hypertension, Hypotension, and eGFR Decrease.

    Time frame: Until end of study (EOS) (Week 56) or Unscheduled visit or end of treatment or early termination (up to 32 months)

  15. Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Microalbuminuria

    Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, was evaluated.

    Time frame: From baseline to Week 12, Week 24, and Week 48

  16. Percentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Microalbuminuria

    Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline was evaluated.

    Time frame: From baseline to Week 12, Week 24, and Week 48

  17. Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria

    Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.

    Time frame: From Week 48 to Week 52

  18. Percentage Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria

    Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.

    Time frame: From Week 48 to Week 52

  19. Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria

    Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.

    Time frame: From Week 48 to Week 52

  20. Percentage Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria

    Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.

    Time frame: From Week 48 to Week 52

07

Results

Posted Nov 4, 2026
Limitations and caveats
The IDMC terminated the study early as the prespecified futility criteria were met at the time of pre-planned interim analysis. Data from one study site (site 508) were excluded due to data reliability and integrity concerns. As Novo Nordisk A/S was not the study sponsor while the trial was ongoing, it cannot confirm the accuracy of factual assertions contained herein concerning the conduct of the study.

Participant flow

Study was conducted at 132 sites in 21 countries globally. Data from site 508 was excluded due to reliability concerns. 666 participants were enrolled (in Run-In Period) in the study and 556 participants were randomized in the double-blind period. 497 participants who completed double-blind period moved to open-label period. 243 participants who completed open-label KBP-5074 treatment were randomized to continue KBP-5074 or receive matching placebo in the double-blind withdrawal period.

Double-Blind Period
Participant flow — Double-Blind Period
MilestoneDouble-blind Treatment Period: KBP-5074Double-blind Treatment Period: PlaceboOpen-label (OL) Treatment Period: KBP-5074 OLRandomization Double-blind Withdrawal (W) Period: KBP-5074-WRandomization Double-blind Withdrawal (W) Period: Placebo-W
Started281275000
Completed251246000
Not completed3029000
Withdrew: Withdrawal by subject2020000
Withdrew: Noncompliance with the protocol01000
Withdrew: Noncompliance with study drug01000
Withdrew: Adverse event20000
Withdrew: Death20000
Withdrew: Study terminated by sponsor12000
Withdrew: Lost to follow-up53000
Withdrew: Randomized in error02000
Open-Label Period
Participant flow — Open-Label Period
MilestoneDouble-blind Treatment Period: KBP-5074Double-blind Treatment Period: PlaceboOpen-label (OL) Treatment Period: KBP-5074 OLRandomization Double-blind Withdrawal (W) Period: KBP-5074-WRandomization Double-blind Withdrawal (W) Period: Placebo-W
Started0049700
Completed0024300
Not completed0025400
Withdrew: Withdrawal by subject001500
Withdrew: Noncompliance with the protocol00100
Withdrew: Adverse event00300
Withdrew: Death00400
Withdrew: Study terminated by sponsor0021000
Withdrew: Trial site terminated by sponsor001500
Withdrew: Lost to follow-up00600
Randomized Double-Blind WithdrawalPeriod
Participant flow — Randomized Double-Blind WithdrawalPeriod
MilestoneDouble-blind Treatment Period: KBP-5074Double-blind Treatment Period: PlaceboOpen-label (OL) Treatment Period: KBP-5074 OLRandomization Double-blind Withdrawal (W) Period: KBP-5074-WRandomization Double-blind Withdrawal (W) Period: Placebo-W
Started000125118
Completed000115108
Not completed0001010
Withdrew: Withdrawal by subject00021
Withdrew: Study terminated by sponsor00068
Withdrew: Trial site terminated by sponsor00020
Withdrew: Lost to follow-up00001

Outcome measures

PrimaryChange in Seated Trough Cuff Systolic Blood Pressure (SBP) From Baseline to Week 12

Efficacy of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for KBP-5074 dose regimen compared to placebo, was evaluated.

Time frame:
From baseline to Week 12
Reported as:
Mean · mm Hg (millimeters of mercury)
Change in Seated Trough Cuff Systolic Blood Pressure (SBP) From Baseline to Week 12
mm Hg (millimeters of mercury)KBP-5074Placebo
Change in Seated Trough Cuff Systolic Blood Pressure (SBP) From Baseline to Week 12-12.9 ± 18.02-12.4 ± 18.73
Statistical analysis
  • KBP-5074 vs Placebo · ANCOVA · p = =0.572 · Difference between adjusted ls means: -0.8 · 95% CI -3.7 to 2Adjusted Least Square (LS) Means were estimated using an analysis of covariance (ANCOVA) model with change in seated trough cuff SBP from baseline to Week 12 as the outcome variable
PrimaryChange in Seated Trough Cuff SBP From Week 48 to Week 52

Durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for the KBP-5074 dose regimen compared to placebo, was evaluated.

Time frame:
From Week 48 to Week 52
Reported as:
Mean · mm Hg
Change in Seated Trough Cuff SBP From Week 48 to Week 52
mm HgKBP-5074Placebo
Change in Seated Trough Cuff SBP From Week 48 to Week 52-0.9 ± 15.450.9 ± 15.91
Statistical analysis
  • KBP-5074 vs Placebo · ANCOVA · p = =0.789 · Difference between adjusted ls means: -0.5 · 95% CI -4.4 to 3.3Adjusted LS Means are estimated using an ANCOVA model with change in seated trough cuff SBP from Week 48 to Week 52 as the outcome variable.
SecondaryChange in Seated Trough Cuff SBP From Baseline to Week 24

Efficacy and durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP, were evaluated.

Time frame:
From baseline to Week 24
Reported as:
Mean · mm Hg
Change in Seated Trough Cuff SBP From Baseline to Week 24
mm HgKBP-5074Placebo
Change in Seated Trough Cuff SBP From Baseline to Week 24-15.3 ± 17.76-12.8 ± 17.30
Statistical analysis
  • KBP-5074 vs Placebo · ANCOVA · p = =0.096 · Difference between adjusted ls means: -2.4 · 95% CI -5.2 to 0.4Adjusted LS Means were estimated using an ANCOVA model with change in seated trough cuff SBP from baseline to Week 24 as the outcome variable.
SecondaryChanges in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 12

Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, was evaluated.

Time frame:
From baseline to Week 12
Reported as:
Mean · mm Hg
Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 12
mm HgKBP-5074Placebo
Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 12-6.3 ± 11.74-5.6 ± 11.53
Statistical analysis
  • KBP-5074 vs Placebo · ANCOVA · p = =0.515 · Difference between adjusted ls means: -0.7 · 95% CI -2.7 to 1.4Adjusted LS Means were estimated using an ANCOVA model with change in seated trough cuff DBP from baseline to Week 12 as the outcome variable.
SecondaryChanges in Urinary Albumin: Creatinine Ratio (UACR) From Baseline to Week 12 for Participants With UACR ≥30 mg/g at Baseline

Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline, was evaluated.

Time frame:
From baseline to Week 12
Reported as:
Median · mg/g (milligram/gram)
Changes in Urinary Albumin: Creatinine Ratio (UACR) From Baseline to Week 12 for Participants With UACR ≥30 mg/g at Baseline
mg/g (milligram/gram)KBP-5074Placebo
Changes in Urinary Albumin: Creatinine Ratio (UACR) From Baseline to Week 12 for Participants With UACR ≥30 mg/g at Baseline-80.43 (-2848.0 to 1091.3)-12.65 (-3261.0 to 4467.8)
Statistical analysis
  • KBP-5074 vs Placebo · ANCOVA · p = =0.331 · Ratio: 0.91 · 95% CI 0.76 to 1.09Adjusted GMRs were estimated using an ANCOVA model with change in log-transformed UACR from baseline to Week 12 as the outcome variable.
SecondaryPercentage Changes in UACR From Baseline to Week 12 and Week 24 for Participants With UACR ≥30 mg/g at Baseline

Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g at baseline, was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.

Time frame:
From baseline to Week 12 and Week 24
Reported as:
Median · Percentage change
Percentage Changes in UACR From Baseline to Week 12 and Week 24 for Participants With UACR ≥30 mg/g at Baseline
Percentage changeKBP-5074Placebo
Week 12-22.43 (-98.0 to 342.7)-9.10 (-99.6 to 3094.4)
Week 24-34.37 (-98.3 to 407.8)-12.50 (-99.5 to 2865.0)
SecondaryChanges in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 24

Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP was evaluated.

Time frame:
From baseline to Week 24
Reported as:
Mean · mm Hg
Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 24
mm HgKBP-5074Placebo
Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 24-6.3 ± 12.09-6.7 ± 12.43
Statistical analysis
  • KBP-5074 vs Placebo · ANCOVA · p = =0.961 · Difference between adjusted ls means: 0.1 · 95% CI -2.1 to 2.2Adjusted LS Means were estimated using an ANCOVA model with change in seated trough cuff DBP from baseline to Week 24 as the outcome variable.
SecondaryChanges in Seated Trough Cuff DBP From Baseline to Week 48

Effect of KBP-5074 on DBP by assessing change in seated trough cuff SBP was evaluated.

Time frame:
From baseline to Week 48
Reported as:
Mean · mm Hg
Changes in Seated Trough Cuff DBP From Baseline to Week 48
mm HgKBP-5074Placebo
Changes in Seated Trough Cuff DBP From Baseline to Week 48-8.1 ± 11.09-10.0 ± 12.00
Statistical analysis
  • KBP-5074 vs Placebo · Mixed Models Analysis · p = =0.244 · Difference in ls means: 1.4 · 95% CI -1 to 3.8Estimated using a mixed-effect repeated model with change in seated trough cuff DBP from baseline to Week 48 as the outcome variable. The model used an Unstructured covariance matrix.
SecondaryChanges in Seated Trough Cuff SBP From Baseline to Week 48

Effect of KBP-5074 on SBP by assessing change in seated trough cuff SBP was evaluated.

Time frame:
From baseline to Week 48
Reported as:
Mean · mm Hg
Changes in Seated Trough Cuff SBP From Baseline to Week 48
mm HgKBP-5074Placebo
Changes in Seated Trough Cuff SBP From Baseline to Week 48-13.1 ± 16.64-17.2 ± 18.23
Statistical analysis
  • KBP-5074 vs Placebo · Mixed Models Analysis · p = =0.095 · Difference between ls means: 2.9 · 95% CI -0.5 to 6.4Estimated using a mixed-effect repeated model with change in seated trough cuff SBP from baseline to Week 48 as the outcome variable. The model uses a Unstructured covariance matrix.
SecondaryChanges in UACR From Baseline to Week 24 for Participants With UACR ≥30 mg/g at Baseline

Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline was evaluated.

Time frame:
From baseline to Week 24
Reported as:
Median · mg/g (milligram/gram)
Changes in UACR From Baseline to Week 24 for Participants With UACR ≥30 mg/g at Baseline
mg/g (milligram/gram)KBP-5074Placebo
Changes in UACR From Baseline to Week 24 for Participants With UACR ≥30 mg/g at Baseline-140.90 (-4503.7 to 1860.8)-11.44 (-3256.2 to 4716.8)
Statistical analysis
  • KBP-5074 vs Placebo · ANCOVA · p = =0.028 · Ratio: 0.77 · 95% CI 0.61 to 0.97Adjusted GMRs are estimated using an ANCOVA model with change in log-transformed UACR from baseline to Week 24 as the outcome variable.
SecondaryChanges in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Macroalbuminuria

Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated.

Time frame:
From baseline to Week 12, Week 24, and Week 48
Reported as:
Median · mg/g
Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Macroalbuminuria
mg/gKBP-5074Placebo
Week 12-252.62 (-2848.0 to 1091.3)-104.83 (-3261.0 to 4467.8)
Week 24-350.58 (-4503.7 to 1860.8)-70.30 (-3256.2 to 4716.8)
Week 48-285.12 (-2599.1 to 838.5)-317.71 (-3567.1 to 4518.3)
Statistical analysis
  • KBP-5074 vs Placebo · Mixed Models Analysis · p = =0.794 · Ratio: 0.97 · 0.75% CI 0.75 to 1.24Estimated using a mixed-effect repeated model with change in log of UACR from baseline to Week 24 as the outcome variable. The model used an Unstructured covariance matrix.
  • KBP-5074 vs Placebo · Mixed Models Analysis · p = =0.004 · Ratio: 0.70 · 95% CI 0.55 to 0.89Estimated using a mixed-effect repeated model with change in log of UACR from baseline to Week 24 as the outcome variable. The model used an Unstructured covariance matrix.
  • KBP-5074 vs Placebo · Mixed Models Analysis · p = =0.147 · Ratio: 0.70 · 95% CI 0.43 to 1.14Estimated using a mixed-effect repeated model with change in log of UACR from baseline to Week 48 as the outcome variable. The model used an Unstructured covariance matrix.
SecondaryPercentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Macroalbuminuria

Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated.

Time frame:
From baseline to Week 12, Week 24, and Week 48
Reported as:
Median · Percentage change
Percentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Macroalbuminuria
Percentage changeKBP-5074Placebo
Week 12-22.54 (-98.0 to 284.0)-11.40 (-99.6 to 197.5)
Week 24-38.74 (-98.3 to 144.2)-12.57 (-99.5 to 386.4)
Week 48-40.20 (-99.5 to 196.4)-47.43 (-99.5 to 1378.4)
SecondaryChange in Seated Trough Cuff DBP From Week 48 to Week 52

Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP was evaluated.

Time frame:
From Week 48 to Week 52
Reported as:
Mean · mm Hg
Change in Seated Trough Cuff DBP From Week 48 to Week 52
mm HgKBP-5074-WPlacebo-W
Change in Seated Trough Cuff DBP From Week 48 to Week 520.6 ± 9.590.6 ± 10.98
SecondaryChange in UACR From Week 48 to Week 52 for Participants With UACR ≥30 mg/g at Baseline

Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.

Time frame:
Week 48 to Week 52
Reported as:
Median · mg/g
Change in UACR From Week 48 to Week 52 for Participants With UACR ≥30 mg/g at Baseline
mg/gKBP-5074-WPlacebo-W
Change in UACR From Week 48 to Week 52 for Participants With UACR ≥30 mg/g at Baseline-17.31 (-523.8 to 5366.4)9.38 (-1320.7 to 3905.9)
Statistical analysis
  • KBP-5074-W vs Placebo-W · ANCOVA · p = =0.113 · Ratio: 0.79 · 95% CI 0.59 to 1.06Estimated using an ANCOVA model with change in log of UACR from Week 48 to Week 52 as the outcome variable.
SecondaryPercentage Change in UACR From Week 48 to Week 52 in Participants With UACR ≥30 mg/g at Baseline

Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.

Time frame:
From Week 48 to Week 52
Reported as:
Median · Percentage change
Percentage Change in UACR From Week 48 to Week 52 in Participants With UACR ≥30 mg/g at Baseline
Percentage changeKBP-5074-WPlacebo-W
Percentage Change in UACR From Week 48 to Week 52 in Participants With UACR ≥30 mg/g at Baseline-15.16 (-76.0 to 132.0)20.23 (-99.5 to 5133.0)
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

The safety and tolerability of KBP-5074 was evaluated. A treatment emergent adverse event (TEAE) was defined as any AE with onset during or after first dose and before 4 weeks after last dose of study drug, or any preexisting AE/condition that worsened during this period. Selected TEAEs include Hyperkalemia, Hypertension, Hypotension, and eGFR Decrease.

Time frame:
Until end of study (EOS) (Week 56) or Unscheduled visit or end of treatment or early termination (up to 32 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsKBP-5074PlaceboKBP-5074 OLKBP-5074-WPlacebo-W
Any TEAE1541542864035
Any TEAE Related to Study Drug40186057
Any Severe TEAEs12161911
Any Severe TEAE Related to Study Drug21000
Any TEAE With Outcome of Death10200
Any Fatal TEAE Related to Study Drug00000
Any Serious TEAE (TESAE)20302741
Any Non-serious TEAE1511512813935
Any Serious TEAE Related to Study Drug01000
Any TEAE Leading to Discontinuation of Treatment1271621
Any TEAE Leading to Discontinuation of Study98600
Any TEAE Leading to Study Drug Reduced02210
Selected TEAEs69431311613
SecondaryChanges in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Microalbuminuria

Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, was evaluated.

Time frame:
From baseline to Week 12, Week 24, and Week 48
Reported as:
Median · mg/g
Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Microalbuminuria
mg/gKBP-5074Placebo
Week 12-10.98 (-180.4 to 503.5)-5.46 (-248.8 to 1095.4)
Week 24-16.96 (-208.5 to 516.0)-7.32 (-214.6 to 1127.2)
Week 48-23.75 (-248.4 to 1715.6)-7.05 (-231.0 to 1622.1)
Statistical analysis
  • KBP-5074 vs Placebo · Mixed Models Analysis · p = =0.167 · Ratio: 0.85 · 95% CI 0.67 to 1.07Estimated using a mixed-effect repeated model with change in log of UACR from baseline to Week 12 as the outcome variable. The model used an Unstructured covariance matrix.
  • KBP-5074 vs Placebo · Mixed Models Analysis · p = =0.090 · Ratio: 0.79 · 95% CI 0.60 to 1.04Estimated using a mixed-effect repeated model with change in log of UACR from baseline to Week 12 as the outcome variable. The model used an Unstructured covariance matrix.
  • KBP-5074 vs Placebo · Mixed Models Analysis · p = =0.642 · Ratio: 0.91 · 95% CI 0.60 to 1.36Estimated using a mixed-effect repeated model with change in log of UACR from baseline to Week 12 as the outcome variable. The model used an Unstructured covariance matrix.
SecondaryPercentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Microalbuminuria

Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline was evaluated.

Time frame:
From baseline to Week 12, Week 24, and Week 48
Reported as:
Median · Percentage change
Percentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Microalbuminuria
Percentage changeKBP-5074Placebo
Week 12-22.23 (-91.0 to 342.7)-6.44 (-89.9 to 3094.4)
Week 24-27.93 (-91.5 to 407.8)-12.27 (-92.2 to 2865.0)
Week 48-27.39 (-95.1 to 1977.5)-11.39 (-80.2 to 2976.1)
SecondaryChange in UACR From Week 48 to Week 52 in Participants With Microalbuminuria

Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.

Time frame:
From Week 48 to Week 52
Reported as:
Median · mg/g
Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria
mg/gKBP-5074-WPlacebo-W
Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria-11.76 (-274.8 to 24.2)9.07 (-561.4 to 1547.4)
Statistical analysis
  • KBP-5074-W vs Placebo-W · ANCOVA · p = <0.001 · Ratio: 0.68 · 95% CI 0.55 to 0.83Estimated using an ANCOVA model with change in log of UACR from Week 48 to Week 52 as the outcome variable.
SecondaryPercentage Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria

Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.

Time frame:
From Week 48 to Week 52
Reported as:
Median · Percentage change
Percentage Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria
Percentage changeKBP-5074-WPlacebo-W
Percentage Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria-15.85 (-57.8 to 132.0)26.84 (-64.2 to 246.0)
SecondaryChange in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria

Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.

Time frame:
From Week 48 to Week 52
Reported as:
Median · mg/g
Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria
mg/gKBP-5074-WPlacebo-W
Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria-42.15 (-523.8 to 5366.4)13.66 (-1320.7 to 3905.9)
Statistical analysis
  • KBP-5074-W vs Placebo-W · ANCOVA · p = =0.636 · Ratio: 0.88 · 95% CI 0.51 to 1.51Estimated using an ANCOVA model with change in log of UACR from Week 48 to Week 52 as the outcome variable.
SecondaryPercentage Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria

Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.

Time frame:
From Week 48 to Week 52
Reported as:
Median · Percentage change
Percentage Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria
Percentage changeKBP-5074-WPlacebo-W
Percentage Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria-11.98 (-76.0 to 109.7)7.64 (-99.5 to 5133.0)

Adverse events

Collected over Until end of study (EOS) (Week 56) or Unscheduled visit or end of treatment or early termination (up to 32 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
KBP-50742/281 (0.7%)20/281 (7.1%)39/281 (13.9%)
Placebo0/273 (0%)30/273 (11%)16/273 (5.9%)
KBP-5074 - OL4/469 (0.9%)27/469 (5.8%)83/469 (17.7%)
KBP-5074 - W0/99 (0%)4/99 (4%)13/99 (13.1%)
Placebo - W0/107 (0%)1/107 (0.9%)6/107 (5.6%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventKBP-5074PlaceboKBP-5074 - OLKBP-5074 - WPlacebo - W
PneumoniaInfections and infestations3/2817/2734/4690/990/107
Chronic kidney diseaseRenal and urinary disorders5/2814/2731/4690/990/107
COVID-19Infections and infestations0/2814/2730/4690/990/107
Cerebral infarctionNervous system disorders0/2813/2730/4690/990/107
Acute kidney injuryRenal and urinary disorders3/2811/2732/4690/990/107
HyperkalaemiaMetabolism and nutrition disorders3/2811/2730/4690/990/107
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2811/2730/4691/990/107
Cardiac failure acuteCardiac disorders0/2810/2731/4691/990/107
Malignant melanoma in situNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2810/2730/4691/990/107
Iron deficiency anaemiaBlood and lymphatic system disorders0/2810/2730/4691/990/107
Most frequent other events
Most frequent other events
EventKBP-5074PlaceboKBP-5074 - OLKBP-5074 - WPlacebo - W
HyperkalaemiaMetabolism and nutrition disorders25/2819/27359/4690/990/107
Glomerular filtration rate decreasedInvestigations16/2819/27332/4697/996/107
AnaemiaBlood and lymphatic system disorders0/2810/2730/4696/996/107

Baseline characteristics

The intent to treat (ITT) population was defined as all randomized participants after removal of participants from site 508.

Age, Continuous
Age, Continuous(Years)KBP-5074PlaceboTotal
Mean67.4 ± 10.8767.9 ± 10.8567.6 ± 10.85
Sex: Female, Male
Sex: Female, Male(Participants)KBP-5074PlaceboTotal
Female98116214
Male183159342
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)KBP-5074PlaceboTotal
Hispanic/Latino413980
Not Hispanic/Latino232231463
Not reported6410
Unknown213
08

Study locations

215 sites
  • G & L Research, LLC
    Foley, Alabama 36535, United States
  • Apogee Clinical Research, LLC
    Huntsville, Alabama 35805, United States
  • Aventiv Research, Inc
    Mesa, Arizona 85210, United States
  • National Heart Institute
    Beverly Hills, California 90211-2285, United States
  • Amicis Research Center (Valencia)
    Granada Hills, California 91324, United States
  • Amicis Research Center
    Granada Hills, California 91344, United States
  • Amicis Research Center
    Lancaster, California 93534, United States
  • Renal Consultants Medical Group - Granada Hills
    Northridge, California 91325, United States
  • United Clinical Research and Innovations
    South Gate, California 90280, United States
  • Solano Kidney Care
    Vacaville, California 95687-3557, United States
  • Desert Cities Dialysis - Amethyst
    Victorville, California 92392, United States
  • Kidney and Hypertension Center
    Victorville, California 92395, United States
  • Davita Clinical Research-Hartford
    Bloomfield, Connecticut 06002, United States
  • Synergy Healthcare
    Bradenton, Florida 34208, United States
  • Homestead Associates in Research, Inc
    Miami, Florida 33032-8225, United States
  • Total Research Group
    Miami, Florida 33126-3422, United States
  • LCC Medical Research
    Miami, Florida 33126, United States
  • Oceane 7 Medical&Research Center, Inc.
    Miami, Florida 33144, United States
  • Allied Biomedical Research Institute
    Miami, Florida 33155, United States
  • South Florida Research Phase I-Iv, Inc.
    Miami, Florida 33166, United States
  • San Marcus Research Clinic, Inc.
    Miami Lakes, Florida 33014-5602, United States
  • Inpatient Research Clinic, LLC
    Miami Lakes, Florida 33014, United States
  • New Generation Of Medical Research
    Naples, Florida 34104, United States
  • Sarkis Clinical
    Ocala, Florida 34471, United States
  • Omega Research Orlando, LLC
    Orlando, Florida 32808, United States
  • Genesis Clinical Research
    Tampa, Florida 33603, United States
  • Santos Research Center CORP
    Tampa, Florida 33604, United States
  • Fides Clinical Research
    Atlanta, Georgia 30342, United States
  • Southeastern Clinical Research Institute, LLC
    Augusta, Georgia 30904, United States
  • Columbus Associates LLC
    Columbus, Georgia 31904-3650, United States
  • Central Georgia Kidney Specialists
    Macon, Georgia 31201-6863, United States
  • Clinical Investigation Specialists, Inc.
    Gurney, Illinois 60031, United States
  • Massachusetts General Hospital (MGH) - Renal Associates Clinic
    Boston, Massachusetts 02114, United States
  • InterMed Consultants
    Edina, Minnesota 55435-2129, United States
  • Healthcare Research Network
    Hazelwood, Missouri 63042, United States
  • Clinical Research Consultants
    Kansas City, Missouri 64111-5964, United States
  • St. Louis Heart and Vascular, P.C. (SLHV) - Christian Hospital Office
    St Louis, Missouri 63136-6111, United States
  • Healor Primary Care /CCT Research
    Las Vegas, Nevada 89102-1682, United States
  • DaVita Clinical Research (Nevada)
    Las Vegas, Nevada 89128, United States
  • NYC Health + Hospitals / Queens - Diabetes Center of Excellence
    Jamaica, New York 11432, United States
  • Mattoo & Bhat Medical Associates, PC
    Ridgewood, New York 11385, United States
  • Albert Einstein's College of Medicine
    The Bronx, New York 10461-1900, United States
  • Kidney Medical Associates, PLLC
    The Bronx, New York 10461-2710, United States
  • Mountain Kidney & Hypertension Associates (MKHA), P.A - Asheville
    Asheville, North Carolina 28801-4104, United States
  • Physicians East, PA
    Greenville, North Carolina 27834, United States
  • Eastern Nephrology Associates - Jacksonville
    Jacksonville, North Carolina 28546, United States
  • Eastern Nephrology Associates - New Bern
    New Bern, North Carolina 28562-5200, United States
  • North Carolina Nephrology P.A.
    Raleigh, North Carolina 27609-7511, United States
  • Brookview Hills Research Associates, LLC
    Winston-Salem, North Carolina 27103-7108, United States
  • Providence Health Partners-Center for Clinical Research
    Dayton, Ohio 45439, United States
  • Columbia Nephrology Associates, PA
    Columbia, South Carolina 29203-6476, United States
  • Knoxville Kidney Center, PLLC
    Knoxville, Tennessee 37923-3624, United States
  • Gamma Clinical Research Institute
    Austin, Texas 78503, United States
  • Davita Clinical Research El Paso
    El Paso, Texas 79925, United States
  • Kidney Consultants of El Paso, P.A.
    El Paso, Texas 79935, United States
  • DaVita Clinical Research Houston
    Houston, Texas 77004, United States
  • Pioneer Research Solutions, Inc.
    Houston, Texas 77099, United States
  • Clinical Advancement Center, PLLC
    San Antonio, Texas 78212-4738, United States
  • Urology San Antonio - North Central
    San Antonio, Texas 78229-3342, United States
  • DaVita Clinical Research
    San Antonio, Texas 78251, United States
  • Kidney Specialists of North Houston, PLLC
    The Woodlands, Texas 77384, United States
  • Davita Norfolk Square
    Norfolk, Virginia 23502, United States
  • Dominion Medical Associates, Inc.
    Richmond, Virginia 23219, United States
  • Clinical Investigation Specialists
    Kenosha, Wisconsin 53142, United States
  • Milwaukee Nephrologists, SC (Rich)
    Wauwatosa, Wisconsin 53226, United States
  • Renal Research
    Gosford, New South Wales 2250, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Austin Hospital
    Heidelberg, Victoria 3084, Australia
  • Clinical Center University of Sarajevo
    Sarajevo, Kanton Sarajevo 71000, Bosnia and Herzegovina
  • Univerzitetski klinicki centar Republike Srpske - Internal Medicine, Nephrology
    Banja Luka, Republika Srpska 78000, Bosnia and Herzegovina
  • The University Hospital Foca
    Foca, Republika Srpska 73300, Bosnia and Herzegovina
  • General Hospital Gradiska
    Gradiska, Republika Srpska 78400, Bosnia and Herzegovina
  • General hospital Trebinje - Gastroenterology
    Trebinje, Republika Srpska 89101, Bosnia and Herzegovina
  • General Hospital Tesanj
    Tešanj, Zeničko-dobojski Kanton 72460, Bosnia and Herzegovina
  • 5 th MHAT
    Sofia, Sofia-Grad 1233, Bulgaria
  • Medical Center Excelsior
    Sofia, Sofia-Grad 1407, Bulgaria
  • UMHAT St. Ekaterina
    Sofia, Sofia-Grad 1431, Bulgaria
  • Comac Medical Ltd
    Sofia, Sofia-Grad 1612, Bulgaria
  • Mhat Dr.Tota Venkova
    Gabrovo, 5300, Bulgaria
  • Medical Center Hera EOOD
    Montana, 3400, Bulgaria
  • UMHAT Kaspela
    Plovdiv, 4002, Bulgaria
  • Medical Center "Teodora"
    Rousse, 7012, Bulgaria
  • DCC 22 - Sofia
    Sofia, 1113, Bulgaria
  • Medical Center Hera EOOD
    Sofia, 1510, Bulgaria
  • Medical Center ''Synexus Sofia'' EOOD
    Sofia, 1784, Bulgaria
  • University Hospital of Active Treatment Prof. Stoyan Kirkovich
    Stara Zagora, 6000, Bulgaria
  • MHAT"Sv.Anna-Varna"AD
    Varna, 9002, Bulgaria
  • Dr. Stephen S. Chow Medicine Professional Corporation
    Toronto, Ontario M4C 5T2, Canada
  • Clinical Research Solutions Incorporated
    Waterloo, Ontario N2T 0C1, Canada
  • Beijing Chao-Yang Hospital, Capital Medical University
    Beijing, Beijing Municipality 100020, China
  • Beijing An Zhen Hospital, Capital Medical University
    Beijing, Beijing Municipality 100029, China
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality 100029, China
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
  • Beijing Hospital
    Beijing, Beijing Municipality 100730, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Zhongshan Hospital Xiamen University
    Xiamen, Fujian 361004, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
  • Guangzhou First People's Hospital - Nephrology
    Guangzhou, Guangdong 510180, China
  • The Third Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510655, China

Showing the first 100 of 215 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Jan 2024, 26 months.

Results were first posted in Nov 2026, 2 years 9 months after primary completion. A results delay was requested in Aug 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2021
First posted
Jul 20, 2021
StartActual
Nov 5, 2021
Primary completionActual
Jan 30, 2024
CompletionActual
Jul 10, 2024
Results delay requested
Aug 7, 2024
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Sites
5 sites added, 5 sites removed
Show 5 added (2 Spain, 1 Hungary, 1 South Africa, 1 South Korea)
  • Kistarcsai Flor Ferenc Korhaz · Kistarcsa, Hungary
  • Tiervlei Trial Centre · Cape Town, South Africa
  • Seoul National University Hospital - Nephrology · Seoul, South Korea
  • Hospital público da Mariña · Lugo, Spain
  • Hospital Ribera Polusa · Lugo, Spain
Show 5 removed
  • Kistarcsai Flor Ferenc Korhaz · Kistarcsa Hungary, Hungary
  • Tiervlei Trial Centre · Bellville, Cape Town, South Africa
  • Seoul National University Hospital - Nephrology · Jongno-gu, South Korea
  • Hospital público da Mariña · Burela de Cabo, Spain
  • Hospital Ribera Polusa · Burela de Cabo, Spain
Nov 4, 2026
Enrollment
652→666
Nov 4, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedChange in seated trough cuff Seated Trough Cuff Systolic Blood Pressure (SBP from baseline) From Baseline to Week 12Time frame: From baseline to Week 12
  • EditedChange in seated trough cuffSeated Trough Cuff SBP fromFrom Week 48 to Week 52Time frame: Week 48 to Week 52 → From Week 48 to Week 52
Nov 4, 2026
Documents
Secondary outcomes
11 edited, 9 added
What changed in the outcomes
  • EditedChange in seated trough cuffSeated Trough Cuff SBP from baselineFrom Baseline to Week 24Time frame: From baseline to Week 24
  • EditedChanges in seated trough cuff diastolic blood pressureSeated Trough Cuff Diastolic Blood Pressure (DBP) from baselineFrom Baseline to Week 12 and Week 24Time frame: From baseline to Week 12 and Week 24 → From baseline to Week 12
  • EditedChanges in seated trough cuff SBP and Seated Trough Cuff Diastolic Blood Pressure (DBP from baseline) From Baseline to Week 4824Time frame: From baseline to Week 48 → From baseline to Week 24
  • EditedChanges in urinary albuminUrinary Albumin: creatinine ratioCreatinine Ratio (UACR) from baselineFrom Baseline to Week 12 and Week 24 for participants withParticipants With UACR ≥30 mg/g at baselineBaselineTime frame: From baseline to Week 12 and Week 24 → From baseline to Week 12
  • EditedPercentage changesChanges in UACR from baselineFrom Baseline to Week 12 and Week 24 for participants withParticipants With UACR ≥30 mg/g at baselineBaselineTime frame: From baseline to Week 12 and Week 24
  • EditedChanges in UACR from baselineSeated Trough Cuff DBP From Baseline to Week 12, Week 24, and Week 48Time frame: From baseline to Week 12, Week 24, and Week 48 → From baseline to Week 48
  • EditedPercentage changesChanges in UACR from baselineSeated Trough Cuff SBP From Baseline to Week 12, Week 24, and Week 48Time frame: From baseline to Week 12, Week 24, and Week 48 → From baseline to Week 48
  • EditedChange in seated trough cuffSeated Trough Cuff DBP fromFrom Week 48 to Week 52Time frame: Week 48 to Week 52 → From Week 48 to Week 52
  • EditedChange in UACR fromFrom Week 48 to Week 52 for Participants With UACR ≥30 mg/g at BaselineTime frame: Week 48 to Week 52
  • EditedPercentage changeChange in UACR fromFrom Week 48 to Week 52 in Participants With UACR ≥30 mg/g at BaselineTime frame: Week 48 to Week 52 → From Week 48 to Week 52
  • EditedNumber of participants with adverse eventsParticipants With Adverse Events (AEs) and serious adverse eventsSerious Adverse Events (SAEs)Time frame: Screening (Week -6 to -2) until EOS (Week 56) or Unscheduled visit or end of treatment or early termination → Until end of study (EOS) (Week 56) or Unscheduled visit or end of treatment or early termination (up to 32 months)
  • AddedChanges in UACR From Baseline to Week 24 for Participants With UACR ≥30 mg/g at BaselineTime frame: From baseline to Week 24
  • AddedChanges in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With MacroalbuminuriaTime frame: From baseline to Week 12, Week 24, and Week 48
  • AddedPercentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With MacroalbuminuriaTime frame: From baseline to Week 12, Week 24, and Week 48
  • AddedChanges in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With MicroalbuminuriaTime frame: From baseline to Week 12, Week 24, and Week 48
  • AddedPercentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With MicroalbuminuriaTime frame: From baseline to Week 12, Week 24, and Week 48
  • AddedChange in UACR From Week 48 to Week 52 in Participants With MicroalbuminuriaTime frame: From Week 48 to Week 52
  • AddedPercentage Change in UACR From Week 48 to Week 52 in Participants With MicroalbuminuriaTime frame: From Week 48 to Week 52
  • AddedChange in UACR From Week 48 to Week 52 in Participants With MacroalbuminuriaTime frame: From Week 48 to Week 52
  • AddedPercentage Change in UACR From Week 48 to Week 52 in Participants With MacroalbuminuriaTime frame: From Week 48 to Week 52
Nov 4, 2026
Sponsor
KBP Biosciences→Novo Nordisk A/S
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    5 sites added, 5 sites removed
    Show 5 added (2 Spain, 1 Hungary, 1 South Africa, 1 South Korea)
    • Kistarcsai Flor Ferenc Korhaz · Kistarcsa, Hungary
    • Tiervlei Trial Centre · Cape Town, South Africa
    • Seoul National University Hospital - Nephrology · Seoul, South Korea
    • Hospital público da Mariña · Lugo, Spain
    • Hospital Ribera Polusa · Lugo, Spain
    Show 5 removed
    • Kistarcsai Flor Ferenc Korhaz · Kistarcsa Hungary, Hungary
    • Tiervlei Trial Centre · Bellville, Cape Town, South Africa
    • Seoul National University Hospital - Nephrology · Jongno-gu, South Korea
    • Hospital público da Mariña · Burela de Cabo, Spain
    • Hospital Ribera Polusa · Burela de Cabo, Spain
    Enrollment 652→666
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedChange in seated trough cuff Seated Trough Cuff Systolic Blood Pressure (SBP from baseline) From Baseline to Week 12Time frame: From baseline to Week 12
    • EditedChange in seated trough cuffSeated Trough Cuff SBP fromFrom Week 48 to Week 52Time frame: Week 48 to Week 52 → From Week 48 to Week 52
    Secondary outcomes 11 edited, 9 added
    What changed in the outcomes
    • EditedChange in seated trough cuffSeated Trough Cuff SBP from baselineFrom Baseline to Week 24Time frame: From baseline to Week 24
    • EditedChanges in seated trough cuff diastolic blood pressureSeated Trough Cuff Diastolic Blood Pressure (DBP) from baselineFrom Baseline to Week 12 and Week 24Time frame: From baseline to Week 12 and Week 24 → From baseline to Week 12
    • EditedChanges in seated trough cuff SBP and Seated Trough Cuff Diastolic Blood Pressure (DBP from baseline) From Baseline to Week 4824Time frame: From baseline to Week 48 → From baseline to Week 24
    • EditedChanges in urinary albuminUrinary Albumin: creatinine ratioCreatinine Ratio (UACR) from baselineFrom Baseline to Week 12 and Week 24 for participants withParticipants With UACR ≥30 mg/g at baselineBaselineTime frame: From baseline to Week 12 and Week 24 → From baseline to Week 12
    • EditedPercentage changesChanges in UACR from baselineFrom Baseline to Week 12 and Week 24 for participants withParticipants With UACR ≥30 mg/g at baselineBaselineTime frame: From baseline to Week 12 and Week 24
    • EditedChanges in UACR from baselineSeated Trough Cuff DBP From Baseline to Week 12, Week 24, and Week 48Time frame: From baseline to Week 12, Week 24, and Week 48 → From baseline to Week 48
    • EditedPercentage changesChanges in UACR from baselineSeated Trough Cuff SBP From Baseline to Week 12, Week 24, and Week 48Time frame: From baseline to Week 12, Week 24, and Week 48 → From baseline to Week 48
    • EditedChange in seated trough cuffSeated Trough Cuff DBP fromFrom Week 48 to Week 52Time frame: Week 48 to Week 52 → From Week 48 to Week 52
    • EditedChange in UACR fromFrom Week 48 to Week 52 for Participants With UACR ≥30 mg/g at BaselineTime frame: Week 48 to Week 52
    • EditedPercentage changeChange in UACR fromFrom Week 48 to Week 52 in Participants With UACR ≥30 mg/g at BaselineTime frame: Week 48 to Week 52 → From Week 48 to Week 52
    • EditedNumber of participants with adverse eventsParticipants With Adverse Events (AEs) and serious adverse eventsSerious Adverse Events (SAEs)Time frame: Screening (Week -6 to -2) until EOS (Week 56) or Unscheduled visit or end of treatment or early termination → Until end of study (EOS) (Week 56) or Unscheduled visit or end of treatment or early termination (up to 32 months)
    • AddedChanges in UACR From Baseline to Week 24 for Participants With UACR ≥30 mg/g at BaselineTime frame: From baseline to Week 24
    • AddedChanges in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With MacroalbuminuriaTime frame: From baseline to Week 12, Week 24, and Week 48
    • AddedPercentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With MacroalbuminuriaTime frame: From baseline to Week 12, Week 24, and Week 48
    • AddedChanges in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With MicroalbuminuriaTime frame: From baseline to Week 12, Week 24, and Week 48
    • AddedPercentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With MicroalbuminuriaTime frame: From baseline to Week 12, Week 24, and Week 48
    • AddedChange in UACR From Week 48 to Week 52 in Participants With MicroalbuminuriaTime frame: From Week 48 to Week 52
    • AddedPercentage Change in UACR From Week 48 to Week 52 in Participants With MicroalbuminuriaTime frame: From Week 48 to Week 52
    • AddedChange in UACR From Week 48 to Week 52 in Participants With MacroalbuminuriaTime frame: From Week 48 to Week 52
    • AddedPercentage Change in UACR From Week 48 to Week 52 in Participants With MacroalbuminuriaTime frame: From Week 48 to Week 52
    Sponsor KBP Biosciences→Novo Nordisk A/S
    + 5 other changes: identifiers, verification date, registry dates, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04968184
Lead sponsor
Novo Nordisk A/S
Collaborators
KBP Biosciences
Responsible party
Sponsor
First posted
Jul 20, 2021
Start date
Nov 5, 2021
Primary completion
Jan 30, 2024
Completion
Jul 10, 2024
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KBP-5074

Start the discussion